Skip to content

Brain Stimulation, Clinical Symptoms and Cognition

Transcranial Direct Current Stimulation (tDCS) Studies of Auditory Hallucinations, Negative Symptoms and Cognition in Schizophrenia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05053451
Enrollment
5
Registered
2021-09-22
Start date
2021-09-14
Completion date
2024-04-10
Last updated
2024-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

schizophrenia, EEG, tDCS, dorsolateral prefrontal cortex, temporoparietal junction, cognitive control, auditory hallucinations, transcranial direct current stimulation

Brief summary

The purpose of this study is to test the impact of non-invasive brain stimulation, transcranial direct current stimulation (tDCS), on auditory hallucinations, negative symptoms and cognition in schizophrenia. Clinical measures will be used to assess clinical symptoms and cognitive performance to test the hypothesis that a course of tDCS can reduce auditory hallucinations and negative symptoms in schizophrenia.

Interventions

DEVICETranscranial Direct Current Stimulation

In tDCS, saline-soaked electrodes are temporarily affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (20 minutes) to stimulate the targeted brain area (e.g. the DLPFC, TPJ, Occipital Cortex) depending on the phase of the study.

Sponsors

University of California, Davis
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Participants must be able to sufficiently speak and understand English so as to be able to understand and complete cognitive tasks. * All subjects must have the ability to give valid informed consent. * No children under the age of 18 will be recruited. * Diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder * Stable outpatient or partial hospital status * Normal IQ (\>70; IQ will be measured by administering the Wechsler Abbreviated Scale of Intelligence (WASI) test)

Exclusion criteria

* Pacemakers * Implanted electrical (brain and spinal) stimulators * Implanted defibrillator * Metallic implants * Skin damage or skin conditions such as eczema at the sites where electrodes will be placed * Hair styles hindering the placement of electrodes * Cranial pathologies * Head trauma * Epilepsy * Mental retardation * Any known history of neurological disorders (including epilepsy, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, cerebral palsy, any DSM-5 axis I psychiatric disorder (for healthy control subjects), autism) * Uncorrected vision problems that would hinder cognitive testing (this also pertains to subjects with color blindness in tasks where discriminating colored objects/items is necessary for successful performance) * Pregnancy * Substance dependence in the past six months * Substance abuse in the past month

Design outcomes

Primary

MeasureTime frameDescription
Change in Symptom Severity of Auditory HallucinationsAssessment begins with the initial baseline interview and concludes after a 2-week follow-up assessment using the same clinical measures.Participants will undergo diagnostic (clinical) interviews to rate their symptom severity using measures including, but not limited to, the Brief Psychiatric Rating Scale (rated 1-7, with a high rating indicating more severe symptoms), the Scale of the Assessment of Positive Symptoms (rated 0-5, with a high rating indicating more severe symptoms), and the Scale for the Assessment or Negative Symptoms (rated 0-5, with a high rating indicating more severe symptoms).
Change in Symptom Severity of Negative SymptomsAssessment begins with the initial baseline interview and concludes after a 2-week follow-up assessment using the same clinical measures.Participants will undergo diagnostic (clinical) interviews to rate their symptom severity using measures including, but not limited to, the Brief Psychiatric Rating Scale (rated 1-7, with a high rating indicating more severe symptoms), the Scale of the Assessment of Positive Symptoms (rated 0-5, with a high rating indicating more severe symptoms), and the Scale for the Assessment or Negative Symptoms (rated 0-5, with a high rating indicating more severe symptoms).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026